Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 38 clinical trials
Clinical Trial Evaluating Methotrexate or Leflunomide + Targeted Therapy Versus Methotrexate or Leflunomide + Sulfasalazine + Hydroxychloroquine in Patients With Rheumatoid Arthritis and Insufficient Response to Methotrexate or Leflunomide (BIO3)

unclear. Rheumatologists are currently used to adding a targeted therapy, such as anti-TNFα, and more recently abatacept or tocilizumab. Triple therapy using 3 conventional disease-modifying drugs (DMARDs

baricitinib
tofacitinib
rituximab
certolizumab pegol
cyclic citrullinated peptide antibody
  • 0 views
  • 24 Jul, 2022
  • 1 location
BIOTIPRA: BIOmarker-guided Treatment Decisions In Psoriatic and Rheumatoid Arthritis (BIOTIPRA)

). Neutralising anti-drug antibodies against the TNFi etanercept or the T-cell co-stimulation inhibitor abatacept have not been detected (10, 12, 15). Furthermore whilst the use and dose of methotrexate at

infliximab
rheumatoid arthritis
methotrexate
etanercept
biological drug
  • 1 views
  • 19 Jun, 2022
  • 7 locations
JAKPOT (JAK Inhibitors and Predictors of Outcome in rheumaToid Arthritis) (JAKPOT)

Rheumatoid arthritis (RA) is a chronic, progressive autoimmune disease associated with inflammation and destruction of joints and systemic effects, which result in significant impact on patient's quality of life and function. Sustained remission or low disease activity is the target to achieve in RA management. Ultrasound (US) is an imaging …

synovitis
tumour necrosis
baricitinib
tumor necrosis factor alpha
tofacitinib
  • 22 views
  • 19 Feb, 2022
  • 1 location
PRI-VENT FSGS: Preemptive Rituximab to Prevent Recurrent Focal Segmental Glomerulosclerosis Post-Transplant

This is a phase III, multicenter, randomized, open label, clinical trial to test that hypothesis that plasmapheresis plus rituximab prior to kidney transplantation can prevent recurrent FSGS in children and adults.

investigational drug
hepatitis c
proteinuria
nephrotic syndrome
minimal change disease
  • 102 views
  • 12 Feb, 2022
  • 14 locations
Persistence of Biological Treatment and Inhibitors of Jak Kinases in Patients With Rheumatoid Arthritis.

One-center observational study aimed at determining the survival of patients with rheumatoid arthritis treated with targeted synthetic disease-modifying drugs (FAMEsd) and biologic disease-modifying drugs (FAMEb). These patients will be administered a series of medications and a follow-up will be carried out to analyze their evolution.

  • 0 views
  • 24 Nov, 2021
  • 1 location
An Observational Registry of Abatacept in Patients With Juvenile Idiopathic Arthritis

The purpose of this study is to examine the long-term safety of Abatacept for the treatment of juvenile idiopathic arthritis (JIA) with particular in interest in the occurrence of serious

arthritis
abatacept
cancer
  • 578 views
  • 11 Jul, 2022
  • 19 locations
Prediction of Abatacept Discontinuation Using Test Reflecting Immunological Remission in Rheumatoid Arthritis

The objective of this study is to identify a panel of immunological molecular and cellular biomarkers able to predict the success of major dose-reduction or discontinuation of abatacept in

leflunomide
synovitis
methotrexate
corticosteroids
remission
  • 0 views
  • 25 Jan, 2021
  • 1 location
New Biomarkers for Diagnosis and Follow-up of Patients With LRBA or CTLA4 Deficiencies

therapy for patients, discover disease related new pathways and biomarkers that can be helpful during diagnosis and monitoring abatacept targeted therapy responses.

  • 42 views
  • 25 Jan, 2021
  • 1 location